158 related articles for article (PubMed ID: 38415667)
1. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Antibacterial Contezolid Acefosamil: Innovative
Liu J; Wang W; Wang C; Zhang L; Zhang X; Liu S; Xu Y; Wang H; Dai Q; Liu C; Wang X; Yuan Z; Gordeev MF
ACS Med Chem Lett; 2022 Jul; 13(7):1030-1035. PubMed ID: 35859881
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration.
Wang XK; Yu J; Xie CY; Hu XX; Nie TY; Li X; Wang PH; Li GQ; Yuan H; Yang XY; Li CR; You XF
J Antimicrob Chemother; 2023 Jul; 78(7):1632-1636. PubMed ID: 37202829
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Wang W; Voss KM; Liu J; Gordeev MF
Chem Res Toxicol; 2021 May; 34(5):1348-1354. PubMed ID: 33913699
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections.
Yuan H; Wu H; Zhang Y; Huang H; Li Y; Wu J; Cao G; Yu J; Guo B; Wu J; Yuan Z; Chen Y; Yang W; Wu X; Zhang J
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0243021. PubMed ID: 35575579
[TBL] [Abstract][Full Text] [Related]
10. Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.
Eckburg PB; Ge Y; Hafkin B
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167545
[TBL] [Abstract][Full Text] [Related]
11. Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Wu X; Li Y; Zhang J; Zhang Y; Yu J; Cao G; Chen Y; Guo B; Shi Y; Huang J; Cao Y; Liu X; Wu J; Gordeev MF; Yuan H; Wang W
Clin Ther; 2018 Feb; 40(2):322-332.e5. PubMed ID: 29398160
[TBL] [Abstract][Full Text] [Related]
12. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.
Wu J; Cao G; Wu H; Chen Y; Guo B; Wu X; Yu J; Ni K; Qian J; Wang L; Wu J; Wang Y; Yuan H; Zhang J; Xi Y
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229495
[TBL] [Abstract][Full Text] [Related]
14. Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis.
Wu J; Yang X; Wu J; Wang J; Wu H; Wang Y; Yuan H; Yang H; Wang H; Zhang J
Front Pharmacol; 2023; 14():1135007. PubMed ID: 36992830
[No Abstract] [Full Text] [Related]
15. Contezolid: First Approval.
Hoy SM
Drugs; 2021 Sep; 81(13):1587-1591. PubMed ID: 34365606
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Wu X; Meng J; Yuan H; Zhong D; Yu J; Cao G; Liu X; Guo B; Chen Y; Li Y; Shi Y; Gordeev MF; Wu J; Zhang J
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0040921. PubMed ID: 34398672
[TBL] [Abstract][Full Text] [Related]
17. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment.
Wang Y; Wu H; Wu J; Fan Y; Liu X; Li Y; Hu J; Zhang J; Guo B
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Feb; 1191():123129. PubMed ID: 35066246
[TBL] [Abstract][Full Text] [Related]
19. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
[TBL] [Abstract][Full Text] [Related]
20. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections.
Zhao X; Huang H; Yuan H; Yuan Z; Zhang Y
J Antimicrob Chemother; 2022 May; 77(6):1762-1769. PubMed ID: 35265985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
